DBV Technologies S.A. - American Depositary Shares (DBVT)
NASDAQ:DBVT
Want to see DBVT full AI Analyst Report?
DBVT Stock Chart & Stats
$21.34
$0.34(9.80%)
At close: 4:00 PM EST
$21.34
$0.34(9.80%)
Day’s Range― - ―
52-Week Range$8.48 - $26.19
Previous CloseN/A
Volume52.91K
Average Volume (3M)214.16K
Market Cap
$972.80M
Enterprise Value$439.45M
Total Cash (Recent Filing)$229.20M
Total Debt (Recent Filing)$16.30M
Price to Earnings (P/E)―
Beta0.03
Next Earnings
Jul 29, 2026EPS Estimate
-0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.93
Shares Outstanding59,212,300
10 Day Avg. Volume296,538
30 Day Avg. Volume214,158
Financial Highlights & Ratios
PEG Ratio-0.27
Price to Book (P/B)9.81
Price to Sales (P/S)0.00
P/FCF Ratio-13.67
Enterprise Value/Market Cap0.45
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-49.37
Enterprise Value/Ebitda-2.76
Forecast
1Y Price Target
$40.97Price Target Upside91.98% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)-1.02
Revenue Forecast (FY)$4.36M
Bulls Say, Bears Say
Bulls Say
Low Financial Leverage And Improved Equity CushionDBV's low debt and a meaningful increase in equity provide a durable solvency buffer that reduces default risk and preserves strategic optionality. For a clinical-stage biotech, a stronger equity cushion lengthens runway and gives management time to advance trials or negotiate deals without immediate refinancing pressure.
Proprietary Viaskin EPIT Platform Addressing Food AllergiesDBV's Viaskin EPIT platform is a differentiated, non-invasive technology applicable to multiple allergens. As a platform, it creates optionality: successful clinical outcomes for one indication can be leveraged across others, enabling scalable long-term revenue streams and strategic partnerships if regulatory and commercial milestones are met.
Shareholder-approved Governance And Capital FlexibilityBoard-authorized capital tools and governance changes strengthen strategic flexibility: they enable timely equity raises, M&A, buybacks or incentive plans as needed. Formalizing CEO succession and updating bylaws also improves governance stability, aiding long-term planning and investor confidence during development phases.
Bears Say
No Commercial Revenue; Wholly Development-stageDBV currently generates no product revenue and remains dependent on clinical progress and external financing. This structural lack of commercial cash flow means operational sustainability hinges on trial success, licensing, or raises; until commercialization, business viability is tied to binary clinical and regulatory outcomes.
Sustained Large Operating Cash BurnPersistent negative operating and free cash flow of roughly -$151M TTM indicates the company is continuously consuming capital to fund R&D without offsetting inflows. This creates a durable need for external financing, raising dilution and execution risk if capital markets tighten or trial timelines extend.
Large Net Losses And Negative Return On EquityMaterial net losses and negative ROE reflect structural inability to generate profits from current operations. Continued erosion of equity undermines long-term shareholder value and restricts reinvestment capacity, making the company reliant on external capital or transformational partnerships to reverse negative returns.
DBV Technologies SA - American News
DBVT FAQ
What was DBV Technologies S.A. - American Depositary Shares’s price range in the past 12 months?
DBV Technologies S.A. - American Depositary Shares lowest stock price was $8.48 and its highest was $26.18 in the past 12 months.
What is DBV Technologies S.A. - American Depositary Shares’s market cap?
DBV Technologies S.A. - American Depositary Shares’s market cap is $972.80M.
When is DBV Technologies S.A. - American Depositary Shares’s upcoming earnings report date?
DBV Technologies S.A. - American Depositary Shares’s upcoming earnings report date is Jul 29, 2026 which is in 52 days.
How were DBV Technologies S.A. - American Depositary Shares’s earnings last quarter?
DBV Technologies S.A. - American Depositary Shares released its earnings results on Apr 30, 2026. The company reported -$0.11 earnings per share for the quarter, beating the consensus estimate of -$0.134 by $0.024.
Is DBV Technologies S.A. - American Depositary Shares overvalued?
According to Wall Street analysts DBV Technologies S.A. - American Depositary Shares’s price is currently Undervalued.
Does DBV Technologies S.A. - American Depositary Shares pay dividends?
DBV Technologies S.A. - American Depositary Shares does not currently pay dividends.
What is DBV Technologies S.A. - American Depositary Shares’s EPS estimate?
DBV Technologies S.A. - American Depositary Shares’s EPS estimate is -0.11.
How many shares outstanding does DBV Technologies S.A. - American Depositary Shares have?
DBV Technologies S.A. - American Depositary Shares has 59,212,300 shares outstanding.
What happened to DBV Technologies S.A. - American Depositary Shares’s price movement after its last earnings report?
DBV Technologies S.A. - American Depositary Shares reported an EPS of -$0.11 in its last earnings report, beating expectations of -$0.134. Following the earnings report the stock price went down -5.381%.
Which hedge fund is a major shareholder of DBV Technologies S.A. - American Depositary Shares?
Currently, no hedge funds are holding shares in DBVT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
DBV Technologies SA - American Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$40.97 (91.98% Upside)
$40.97 (91.98% Upside)
Hedge Fund Trend
Increased
By 1.3M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 20.8%
Last 30 Days ▼ 20.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
94.03%
12-Months-Change
Fundamentals
Return on Equity
-130.06%
Trailing 12-Months
Asset Growth
426.88%
Trailing 12-Months
Company Description
DBV Technologies S.A. - American Depositary Shares
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. The milk-induced company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA); Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordetella pertussis. Its other earlier stage research programs include a vaccine for the respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.
DBVT Stock 12 Month Forecast
Average Price Target
$40.97
▲(91.98% Upside)
Technical Analysis
Larimar Therapeutics
―
Korro Bio
―
4D Molecular Therapeutics
―
―
Lexeo Therapeutics, Inc.
―
Ownership Overview
62.50% Insiders
2.33% Mutual Funds
32.54% Other Institutional Investors
2.56% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---